Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon® N Clinical Trial on Closely Related Flavivirus (West Nile)

PHILADELPHIA, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that it is beginning to consider study designs for potential tests of the activity and...
February 03, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value

PHILADELPHIA, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today, February 3, 2016, a Voluntary Pay for Stock Plan (the “Plan”). Hemispherx Biopharma...
January 20, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)

PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”) announces that the European Medicines Agency (EMA) on January 6, 2016 has...
November 17, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2015

PHILADELPHIA, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the nine months ended September 30, 2015. The net loss (including non-cash...
October 19, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)

PHILADELPHIA, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announces that the European subsidiary, “Hemispherx Biopharma Europe...
September 30, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma

PHILADELPHIA, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announces that Arrowhead BID issued an analyst report on September 29, 2015,...
September 28, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations

PHILADELPHIA, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the...
September 23, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis

PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...
September 21, 2015 09:26 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive of Improved Response to Ampligen

PHILADELPHIA, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announces the publication of an online peer reviewed research article of an analysis of clinical data on its...
September 17, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study

PHILADELPHIA, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the approval by the Board of Directors for a Patient...